Education
About Us
Working with TipRanks
Follow Us
Cosmos Holdings Inc (COSM)
NASDAQ:COSM
Top Page
Cosmos Holdings
(NASDAQ:COSM)
41Neutral
Cosmos Holdings (COSM) vs. S&P 500 (SPY)
Market Cap
$12.28M
Dividend YieldN/A
Average Volume (3M)444.28K
Price to Earnings (P/E)―
Beta (1Y)1.97
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees149
SectorHealthcare
Sector Strength57
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.72
Shares Outstanding27,284,658
10 Day Avg. Volume921,101
30 Day Avg. Volume444,283
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.48
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cosmos Holdings Business Overview & Revenue Model
Company DescriptionCosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
How the Company Makes MoneyCosmos Holdings generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around the distribution of branded and generic medications to pharmacies, hospitals, and clinics. In addition to its core pharmaceutical offerings, Cosmos Holdings also engages in the sale of nutraceuticals and other health-related products. Strategic partnerships with healthcare providers and distribution networks play a crucial role in broadening the company's market reach and enhancing its earnings potential. By leveraging its extensive distribution network and product portfolio, Cosmos Holdings continues to expand its presence in the global healthcare market.
Cosmos Holdings Financial Statement Overview
Summary
Cosmos Holdings exhibits challenging financial performance with negative EBIT and net income, indicating operational inefficiencies. The high debt-to-equity ratio poses financial risk, and persistent negative cash flows reflect liquidity challenges. Minor revenue and equity improvements are overshadowed by significant financial issues.Income Statement
Cosmos Holdings exhibits a challenging financial performance with consistently negative EBIT and net income, indicating operational inefficiencies. The gross profit margin remains low, and recent revenue growth is moderate, but the company has not been able to translate it to profitability. The negative EBITDA and EBIT margins further highlight the lack of operational profitability.35
Negative
Balance Sheet
The balance sheet shows a high debt-to-equity ratio, reflecting significant leverage, which poses financial risk. The equity ratio indicates moderate reliance on equity financing. Recent improvements in stockholders' equity are positive but overshadowed by substantial liabilities, suggesting potential financial instability.40
Negative
Cash Flow
Cash flow analysis shows persistent negative operating and free cash flows, indicating liquidity challenges. The negative free cash flow growth rate highlights ongoing cash consumption. The cash flow from operations does not cover net income, reflecting cash management issues.30
Negative
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 53.38M | 50.35M | 56.24M | 55.41M | 39.68M | Gross Profit |
| 4.35M | 5.96M | 8.33M | 8.06M | 3.66M | EBIT |
| -21.83M | -7.47M | -4.53M | 2.71M | -21.93K | EBITDA |
| -17.06M | -8.90M | -3.82M | 3.18M | -988.59K | Net Income Common Stockholders |
| -18.54M | -13.83M | -7.96M | 820.79K | -3.30M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.85M | 20.76M | 293.18K | 851.19K | 281.86K | Total Assets |
| 66.01M | 68.04M | 49.43M | 43.84M | 23.88M | Total Debt |
| 12.42M | 12.03M | 27.12M | 32.04M | 19.29M | Net Debt |
| 8.59M | -8.72M | 26.84M | 31.41M | 19.25M | Total Liabilities |
| 29.97M | 28.38M | 45.05M | 48.01M | 30.34M | Stockholders Equity |
| 36.04M | 39.66M | 4.38M | -4.16M | -6.46M |
| Cash Flow | Free Cash Flow | |||
| -24.80M | -15.25M | -7.99M | -11.62M | -5.46M | Operating Cash Flow |
| -15.64M | -14.87M | -7.10M | -11.50M | -4.79M | Investing Cash Flow |
| -13.76M | -21.50K | -826.82K | -117.74K | 588.93K | Financing Cash Flow |
| 12.69M | 35.05M | 7.27M | 12.46M | 3.59M |
Cosmos Holdings Technical Analysis
Neutral
0.45
Price Trends
0.45
Positive
0.58
Negative
0.76
Negative
Market Momentum
>-0.01
Negative
57.81
Neutral
81.12
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Neutral. The current price of 0.45 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.45, and below the 200-day MA of 0.76, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.81 is Neutral, neither overbought nor oversold. The STOCH value of 81.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COSM.
Cosmos Holdings Risk Analysis
Cosmos Holdings disclosed 10 risk factors in its most recent earnings report. Cosmos Holdings reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cosmos Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% | |
47 Neutral | $16.44M | ― | -8.16% | ― | 35.25% | 81.05% | |
47 Neutral | $8.08M | ― | -18.06% | ― | -30.19% | 75.92% | |
44 Neutral | $6.63M | ― | -384.98% | ― | 9.54% | 74.28% | |
42 Neutral | $12.24M | ― | -291.50% | ― | -22.58% | 82.94% | |
41 Neutral | $12.28M | ― | -58.30% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
COSM
Cosmos Holdings
0.45
-0.22
-32.84%
TXMD
TherapeuticsMD
1.42
-0.54
-27.55%
AYTU
Aytu BioScience
1.31
-1.75
-57.19%
SISI
Shineco
0.87
-17.85
-95.35%
FLGC
Flora Growth
0.63
-0.95
-60.13%
BFRI
Biofrontera
0.72
-1.00
-58.14%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.